Literature DB >> 9443928

Peroxisome proliferator activated receptor-alpha expression in human liver.

C N Palmer1, M H Hsu, K J Griffin, J L Raucy, E F Johnson.   

Abstract

The peroxisome proliferator activated receptor alpha (PPAR) is a member of the steroid/hormone receptor superfamily that mediates the peroxisome proliferator-dependent transcriptional activation of genes encoding several peroxisomal and microsomal enzymes as well as peroxisome proliferation. Human liver is refractory to the pathological effects of peroxisome proliferators that are seen in mice. With the use of RNase protection assays, the ratio of hepatic PPAR alpha mRNA to beta-actin mRNA was found to be 1 order of magnitude lower in humans than that observed in mice. In addition, the isolation of human cDNA for PPAR alpha that does not encode a functional PPAR because it lacks exon 6 as a result of alternate RNA splicing suggested that this process might also diminish the expression of PPAR alpha. RNase protection analysis of total RNA revealed the presence of splice variants lacking exon 6 at significant levels in all 10 human liver samples examined. Supershift analysis using the CYP4A6-Z peroxisome proliferator response element and antisera specific for PPAR alpha revealed easily detectable amounts of PPAR alpha DNA binding activity in mouse liver lysates, whereas human liver lysates contained > 10-fold lower amounts of PPAR alpha DNA binding activity. In contrast to mouse lysates, the amount of PPAR alpha binding in human lysates was generally less than that of other unidentified proteins. These results suggest that although humans retain the coding potential for a functional receptor, the low levels of PPAR alpha expression in liver may be insufficient to compete effectively with other proteins that bind to peroxisome proliferator response elements.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9443928

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  95 in total

1.  Perfluorooctanoic Acid (PFOA)-induced Liver Lesions in Two Strains of Mice Following Developmental Exposures: PPARα Is Not Required.

Authors:  Adam J Filgo; Erin M Quist; Mark J Hoenerhoff; Amy E Brix; Grace E Kissling; Suzanne E Fenton
Journal:  Toxicol Pathol       Date:  2014-11-14       Impact factor: 1.902

2.  Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion.

Authors:  Nisanne S Ghonem; Meenakshisundaram Ananthanarayanan; Carol J Soroka; James L Boyer
Journal:  Hepatology       Date:  2014-01-27       Impact factor: 17.425

3.  Ammonium perfluorooctanoate may cause testosterone reduction by adversely affecting testis in relation to PPARα.

Authors:  Yufei Li; Doni Hikmat Ramdhan; Hisao Naito; Nozomi Yamagishi; Yuki Ito; Yumi Hayashi; Yukie Yanagiba; Ai Okamura; Hazuki Tamada; Frank J Gonzalez; Tamie Nakajima
Journal:  Toxicol Lett       Date:  2011-06-25       Impact factor: 4.372

4.  Mechanisms of resistance of hepatocyte retinoid X receptor alpha-null mice to WY-14,643-induced hepatocyte proliferation and cholestasis.

Authors:  Maxwell Afari Gyamfi; Yu-Jui Yvonne Wan
Journal:  J Biol Chem       Date:  2009-01-27       Impact factor: 5.157

5.  Modulation of fatty acid and bile acid metabolism by peroxisome proliferator-activated receptor α protects against alcoholic liver disease.

Authors:  Heng-Hong Li; John B Tyburski; Yi-Wen Wang; Steve Strawn; Bo-Hyun Moon; Bhaskar V S Kallakury; Frank J Gonzalez; Albert J Fornace
Journal:  Alcohol Clin Exp Res       Date:  2014-04-28       Impact factor: 3.455

6.  Molecular basis of non-responsiveness to peroxisome proliferators: the guinea-pig PPARalpha is functional and mediates peroxisome proliferator-induced hypolipidaemia.

Authors:  A R Bell; R Savory; N J Horley; A I Choudhury; M Dickins; T J Gray; A M Salter; D R Bell
Journal:  Biochem J       Date:  1998-06-15       Impact factor: 3.857

7.  Time course investigation of PPARalpha- and Kupffer cell-dependent effects of WY-14,643 in mouse liver using microarray gene expression.

Authors:  Courtney G Woods; Oksana Kosyk; Blair U Bradford; Pamela K Ross; Amanda M Burns; Michael L Cunningham; Pingping Qu; Joseph G Ibrahim; Ivan Rusyn
Journal:  Toxicol Appl Pharmacol       Date:  2007-09-16       Impact factor: 4.219

Review 8.  Naturally occurring C-terminal splice variants of nuclear receptors.

Authors:  Michiel van der Vaart; Marcel J M Schaaf
Journal:  Nucl Recept Signal       Date:  2009-06-19

9.  A human hepatocyte-bearing mouse: an animal model to predict drug metabolism and effectiveness in humans.

Authors:  Katsutoshi Yoshizato; Chise Tateno
Journal:  PPAR Res       Date:  2009-10-26       Impact factor: 4.964

Review 10.  A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants.

Authors:  Kathryn Z Guyton; Weihsueh A Chiu; Thomas F Bateson; Jennifer Jinot; Cheryl Siegel Scott; Rebecca C Brown; Jane C Caldwell
Journal:  Environ Health Perspect       Date:  2009-05-15       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.